PBF-1129 Market Summary
Key Factors Driving PBF-1129 Growth
1. First-in-Class A2B Receptor Targeting Approach
PBF-1129 targets the adenosine A2B receptor, a key mediator of immunosuppression within the tumor microenvironment. Preclinical studies have demonstrated that A2B blockade can reduce myeloid-derived suppressor cells (MDSCs), enhance dendritic-cell function, and improve anti-tumor T-cell responses. This differentiated mechanism addresses a well-recognized pathway of resistance to immune checkpoint inhibitors, providing a unique positioning within the immuno-oncology landscape.
2. Favorable Safety and Tolerability Profile
In a Phase I dose-escalation study involving 21 heavily pretreated metastatic NSCLC patients, no dose-limiting toxicities were observed across doses ranging from 40 mg to 320 mg daily. Grade ≥3 treatment-related adverse events were uncommon, supporting the feasibility of long-term administration and future combination strategies with immunotherapies. A favorable safety profile is particularly important for oncology agents intended for combination regimens.
3. Pharmacokinetic Profile Supports Once-Daily Oral Dosing
PBF-1129 demonstrated dose-proportional pharmacokinetics, with plasma concentrations increasing from approximately 150 ng/mL at 40 mg to 800 ng/mL at 320 mg. Importantly, the recommended Phase II dose maintained drug concentrations above the A2B receptor IC90 for 24 hours, supporting convenient once-daily oral administration. Oral administration offers a significant competitive advantage compared with many infused immuno-oncology therapies.
4. Potential Synergy with Immune Checkpoint Inhibitors
Although monotherapy activity was modest, preclinical and translational data indicate that A2B inhibition may enhance the efficacy of PD-1/PD-L1 inhibitors. The Phase I study demonstrated reductions in PD-1 expression on CD8+ and CD4+ T cells as well as decreases in immunosuppressive MDSCs, suggesting immune modulation that could augment checkpoint blockade. This has led to ongoing clinical evaluation of PBF-1129 in combination with the PD-1 inhibitor nivolumab.
5. Significant Unmet Need in Immunotherapy-Resistant NSCLC
Despite advances in immunotherapy, a large proportion of metastatic NSCLC patients either fail to respond to checkpoint inhibitors or eventually develop resistance. All patients enrolled in the Phase I study had previously received chemotherapy and PD-1/PD-L1-directed therapies, representing a population with limited treatment options. If combination studies demonstrate meaningful efficacy, PBF-1129 could address a substantial unmet need in this difficult-to-treat setting.
 
PBF-1129 Recent Developments
In February 2024, Palobiofarma had closed a seven-million-euro investment round led by Inveready, through the Inveready Biotech IV fund, the public company Sodena and the company’s founders.
The investment would be used to complete three Phase II clinical trials in which the efficacy of its most advanced products is being studied, namely PBF-680 in patients with chronic obstructive pulmonary disease, PBF-999 in patients with Prader-Willi syndrome and PBF-1129 in patients with non-small cell lung cancer. Additionally, through this operation, the Fitalent fund, owned by NTT Data, exits the company’s shareholding.
 
“PBF-1129 Sales Forecast, and Market Size Analysis – 2034†report provides comprehensive insights of PBF-1129 for potential indication like Non-small cell lung cancer in the 7MM. A detailed picture of PBF-1129’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the PBF-1129 for potential indications. The PBF-1129 market report provides insights about PBF-1129’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current PBF-1129 performance, future market assessments inclusive of the PBF-1129 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of PBF-1129 sales forecasts, along with factors driving its market.
PBF-1129 Drug Summary
PBF-1129 is an investigational, orally administered small-molecule antagonist of the adenosine A2B receptor (A2BAR), developed to counteract the immunosuppressive effects of adenosine within the tumor microenvironment and enhance anti-tumor immune responses. By selectively blocking A2BAR signaling on cancer cells and immune cells, PBF-1129 aims to reduce tumor-promoting inflammation, inhibit cancer cell proliferation and metastasis, and restore immune-mediated tumor killing. The drug has primarily been evaluated in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after chemotherapy and immune checkpoint inhibitor therapy. In a Phase 1 dose-escalation study, PBF-1129 demonstrated a favorable safety and tolerability profile with no dose-limiting toxicities, dose-proportional pharmacokinetics, and evidence of immune modulation, including reductions in PD-1 expression on T cells and myeloid-derived suppressor cells. The recommended Phase 2 dose was established at 320 mg once daily, and the agent is being further explored in combination with immune checkpoint inhibitors such as nivolumab to improve outcomes in immunotherapy-resistant cancers. The report provides PBF-1129’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
 
Scope of the PBF-1129 Market Report
The report provides insights into:
• A comprehensive product overview including the PBF-1129 MoA, description, dosage and administration, research and development activities in potential indication like Non-small cell lung cancer.
• Elaborated details on PBF-1129 regulatory milestones and other development activities have been provided in PBF-1129 market report.
• The report also highlights PBF-1129‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The PBF-1129 market report also covers the patents information, generic entry and impact on cost cut.
• The PBF-1129 market report contains current and forecasted PBF-1129 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The PBF-1129 market report also features the SWOT analysis with analyst views for PBF-1129 in potential indications.
Methodology
The PBF-1129 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
 
PBF-1129 Analytical Perspective by DelveInsight
• In-depth PBF-1129 Market Assessment
This PBF-1129 sales market forecast report provides a detailed market assessment of PBF-1129 for potential indication like Non-small cell lung cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted PBF-1129 sales data uptil 2034.
• PBF-1129 Clinical Assessment
The PBF-1129 market report provides the clinical trials information of PBF-1129 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
PBF-1129 Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
PBF-1129 Market Potential & Revenue Forecast
• Projected market size for the PBF-1129 and its key indications
• Estimated PBF-1129 sales potential (PBF-1129 peak sales forecasts)
• PBF-1129 Pricing strategies and reimbursement landscape
PBF-1129 Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• PBF-1129 Market positioning compared to existing treatments
• PBF-1129 Strengths & weaknesses relative to competitors
PBF-1129 Regulatory & Commercial Milestones
• PBF-1129 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
PBF-1129 Clinical Differentiation
• PBF-1129 Efficacy & safety advantages over existing drugs
• PBF-1129 Unique selling points
 
PBF-1129 Market Report Highlights
• In the coming years, the PBF-1129 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The PBF-1129 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PBF-1129’s dominance.
• Other emerging products for Non-small cell lung cancer are expected to give tough market competition to PBF-1129 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PBF-1129 in potential indications.
• Analyse PBF-1129 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted PBF-1129 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of PBF-1129 in potential indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of PBF-1129? How strong is PBF-1129’s clinical and commercial performance?
• What is PBF-1129’s clinical trial status in each individual indications such as Non-small cell lung cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PBF-1129 Manufacturers?
• What are the key designations that have been granted to PBF-1129 for potential indications? How are they going to impact PBF-1129’s penetration in various geographies?
• What is the current and forecasted PBF-1129 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of PBF-1129 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to PBF-1129 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is PBF-1129? What is the duration of therapy and what are the geographical variations in cost per patient?
